Corporate Banner
Satellite Banner
Pharma Outsourcing
Scientific Community
Become a Member | Sign in
Home>News>This Article

CMC Biologics and OncoSynergy Enter into Agreement

Published: Monday, December 23, 2013
Last Updated: Sunday, December 22, 2013
Bookmark and Share
Agreement to develop and manufacture material for IND enabling studies and phase I clinical trials.

CMC Biologics and OncoSynergy have announced that the two companies entered into an agreement for cell-line development, process development, analytical development and manufacturing of non-GMP material to enable early toxicology testing and cGMP material for IND enabling toxicology studies and Phase I clinical trials.

This work will advance OncoSynergy’s OS2966 monoclonal antibody program based on its “Targeted Synergy” approach - a transformative strategy allowing broad inhibition of multiple
fundamental cancer growth mechanisms with a single drug.

“We look forward to helping advance OncoSynergy’s OS2966 drug platform targeting cancers resistant to currently available therapies,” said Gustavo Mahler, Global Chief Operations Officer
of CMC Biologics. “This contract highlights CMC Biologics’ proven and trusted platform for monoclonal antibody development and manufacturing.”

The project will be executed by CMC Biologics at its Copenhagen development and manufacturing facility. OncoSynergy EU SAS in France will lead the project.

"We are impressed with CMC Biologics’ experience and technical competency in biopharmaceutical development and cGMP manufacturing," said OncoSynergy Co-Founder and CEO, Shawn Carbonell, MD, PhD.

Carbonell continued, “Choosing a partner who can provide a complete solution - from expression of the sequence of interest, to providing material suitable for clinical trials - was a critical decision as we advance our lead candidate. They have also shown flexibility to accommodate our unique program needs as a virtual startup company.”

Further Information
Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,800+ scientific posters on ePosters
  • More than 4,000+ scientific videos on LabTube
  • 35 community eNewsletters

Sign In

Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

CMC Biologics and OncoSynergy Enter into an Agreement
Agreement for accelerated process development and GMP manufacture of an investigational drug to combat Ebola.
Friday, December 19, 2014
CMC Biologics Achieves Authorization for cGMP Commercial Manufacturing by DKMA
Copenhagen biopharmaceutical manufacturing facility expanded to support growing customer demand for clinical and commercial production.
Thursday, October 17, 2013
CMC Biologics Acquires XOMA’s Bay Area Manufacturing Facility
Expansion designed to further support growing customer demand for cGMP clinical and commercial biologics production.
Tuesday, August 07, 2012
Scientific News
Lucentis Effective for Proliferative Diabetic Retinopathy
NIH-funded clinical trial marks first major advance in therapy in 40 years.
Blocking the Transmission Of Malaria Parasites
Vaccine candidate administered for the first time in humans in a phase I clinical trial led by Oxford University’s Jenner Institute, with partners Imaxio and GSK.
First Therapy Appearing to Reverse Decline in Parkinson’s
An FDA-approved drug for leukemia improved cognition, motor skills and non-motor function in patients with Parkinson’s disease and Lewy body dementia in a small clinical trial, say researchers at Georgetown University Medical Center (GUMC).
Gene Therapy Staves Off Blindness from Retinitis Pigmentosa in Canine Model
NIH-funded study suggests therapeutic window may extend to later-stage disease.
Treatment for Rare Bleeding Disorder is Effective
Researchers in Manchester have demonstrated for the first time the relative safety and effectiveness of treatment, eltrombopag, in children with persistent or chronic immune thrombocytopenia (ITP), as part of an international duo of studies.
HIV Vaccine Human Trials Begin
Baltimore-based Institute has begun enrolling volunteers for initial phase 1 clinical trials.
New Therapy Reduces Symptoms of Inherited Enzyme Deficiency
A phase three clinical trial of a new enzyme replacement medication, sebelipase alfa, showed a reduction in multiple disease-related symptoms in children and adults with lysosomal acid lipase deficiency, an inherited enzyme deficiency that can result in scarring of the liver and high cholesterol.
Fixing Holes in the Heart Without Invasive Surgery
UV-light enabled catheter is a medical device which represents a major shift in how cardiac defects are repaired.
Atriva Therapeutics GmbH Develops Innovative Flu Drug
Highly effective against seasonal and pandemic influenza.
Study Removes Cancer Doubt for Multiple Sclerosis Drug
Researchers from Queen Mary University of London are calling on the medical community to reconsider developing a known drug to treat people with relapsing Multiple sclerosis after new evidence shows it does not increase the risk of cancer as previously thought.
Scroll Up
Scroll Down

Skyscraper Banner
Go to LabTube
Go to eposters
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,800+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,000+ scientific videos